Increased expression of <scp>IL</scp>‐17A and limited involvement of <scp>IL</scp>‐23 in patients with palmo‐plantar (<scp>PP</scp>) pustular psoriasis or <scp>PP</scp> pustulosis; results from a randomised controlled trial

Abstract

Taken together these results suggest that ustekinumab at a dose of 45 mg has limited efficacy in PPPP and PPP. IL-17A may have a more important role than IL-23 in patients with PPPP and PPP. Conclusions are limited by the small sample size of this study.